Alkermes plc Alkermes plc

Alkermes plc

ALKS

Rang in aandelen #2637
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Aandeelprijs
$43.05
Marktkapitalisatie
$7.22B
Verandering (1 dag)
4.43%
Verandering (1 jaar)
42.25%
Land
IE
Handel Alkermes plc (ALKS)

Categorie

Healthcare
Aandelsplitsingen voor Alkermes plc (ALKS)
Het aandeel Alkermes plc (symbool: ALKS) heeft in totaal 1 splitsingen ondergaan.
De meest recente splitsing vond plaats op May 15, 2000.
Eén aandeel ALKS dat vóór May 15, 2000 werd gekocht, staat nu gelijk aan 2 aandelen ALKS.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
2000-05-15 2:1 x2 x2
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL